A review on recent advancement and pharmacological management of migraine
1 Department of Pharmacy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India.
2 Department of Pharmacology, Shraddha Institute of Pharmacy, Washim Maharashtra, India.
Review Article
GSC Advanced Research and Reviews, 2024, 21(03), 218–224.
Article DOI: 10.30574/gscarr.2024.21.3.0477
Publication history:
Received on 30 October 2024; revised on 07 December 2024; accepted on 09 December 2024
Abstract:
Modern theories suggest that the primary disorder in migraine takes place within the CNS and that this inspires adjustments in blood vessels within pain-producing intracranial meningeal systems that deliver upward push to headache pain. Migraine is now concept of as a neurovascular ailment it has been proposed that genetic abnormalities may be answerable for changing the response threshold to migraine particular trigger elements in the mind of a migraine compared to a normal individual. the exact nature of the principal disorder that is produced in migraine continues to be not clear and can contain spreading despair-like phenomena and activation of mind stem monoaminergic nuclei that are a part of the primary autonomic, vascular and ache control facilities. it is commonly notion that local vasodilatation of intracranial extracerebral blood vessels and a consequent stimulation of surrounding trigeminal sensory nervous ache pathways is a key mechanism underlying the era of headache ache related to migraine. This activation of the Trigeminovascular device’ is idea to reason the release of vasoactive sensory neuropeptides, mainly CGRP, that boom the ache reaction. The activated trigeminal nerves deliver nociceptive records to significant neurons within the mind stem trigeminal sensory nuclei that in turn relay the ache alerts to better facilities in which headache pain is perceived. it's been hypothesized that these significant neurons may become sensitized as a migraine assault progresses.The ‘triptan’ anti-migraine marketers (e.g. sumatriptan, rizatriptan, zolmitriptan naratriptan) are serotonergic agonists which have been proven to act selectively via inflicting vasoconstriction through 5-HT1B receptors which are expressed in human intracranial arteries and by way of inhibiting nociceptive transmission via an movement at five-HT1D receptors on peripheral trigeminal sensory nerve terminals within the meninges and crucial terminals in brain stem sensory nuclei. these 3 complementary web sites of movement underlie the clinical effectiveness of the 5-HT1B/1D agonists towards migraine headache pain and its related signs and symptoms
Keywords:
Migraine; Headache; Chronic; Inherited; Neurology; CNS; Brain
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
